Benefit-Risk Assessments For Me-Too Drugs Encouraged By FDA
Executive Summary
Sponsors should complete agency’s structured benefit-risk framework to help reviewers better understand the reason the product is needed in the marketplace.
You may also be interested in...
Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy
Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.
Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms
While pain and fatigue are well-recognized symptoms of fibromyalgia, patients testifying at the PDUFA V disease area meeting gave FDA drug review staff insight into other health effects, such as visual disturbances.
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.